The Institute of Cancer Research, London
More than £5 million secured for the ICR from Cancer Research UK’s RadNet programme to fund work in radiotherapy. Cancer Research UK has awarded The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust a substantial £5.14 million through its radiation research network (RadNet) to support pioneering research in radiation therapy.
About Us - The Institute of Cancer Research, London
The ICR is a college of the University of London, and educating and training the next generation of cancer researchers and clinicians is a core part of our mission. Our vision: We will transform the lives of cancer patients through world-class research and education, and by growing our impact on society. Our donors and supporters play a vital ...
Our Research - The Institute of Cancer Research, London
The Institute of Cancer Research, London, has been driving scientific discoveries on cancer and its treatment for more than 100 years. We are internationally renowned for our work into cancer genetics, cancer biology and personalised medicine – and came second of all UK universities in analysis of the 2021 Research Excellence Framework.
Clinical trials - The Institute of Cancer Research, London
The Institute of Cancer Research, London, has a strong track record in progressing research from bench to bedside through state-of-the art clinical trials. From first-in-human studies to large multicentre trials, we’re committed to delivering innovative, practice-changing clinical trials, particularly to assess the latest precision treatments.
About our research - The Institute of Cancer Research, London
About our research. Cancer is a highly complex disease with more than 200 types, each caused by a different combination of genetic defects. Even among patients with a single type of cancer, such as breast or lung cancer, the genetic triggers vary from one person to the next. At The Institute of Cancer Research, London, we believe it is ...
Breast cancer - The Institute of Cancer Research, London
Clinical trials. We led trials establishing the effectiveness of the chemotherapy drug carboplatin – discovered at the ICR – in triple-negative breast cancer, and of the targeted drug palbociclib in advanced, metastatic breast cancer.. Recently, results from the OlympiA trial showed that using the targeted drug olaparib to treat some women with early stage breast cancer and mutations in ...
Our strategy - The Institute of Cancer Research, London
Our strategy to defeat cancer rests on the latest advances in science, and our understanding that cancer evolves within a complex ecosystem of cells, signals and the immune system. We see cancer research as an ecosystem too, with close interconnections between our fantastic research and teaching, and our knowledge exchange work to maximise our ...
Our research excellence - The Institute of Cancer Research, London
The Institute of Cancer Research, London, is the second-ranked academic research centre in the UK - according to the Times Higher Education league table of university research quality and impact compiled from the Research Excellence Framework (REF 2021) - and first for biological sciences. We were also the third-ranked higher education ...
World-class research - The Institute of Cancer Research, London
Our world-class research will run from bench to bedside and back again – taking research findings to patients, and learning from the experience in the clinic. We aim to understand cancer better, and improve diagnosis and treatment for patients, by working across four research themes: Unravel the cancer ecosystem. Diagnose better and earlier.
ICR ranked as one of world’s top research institutes for influence and ...
The Institute of Cancer Research is one of the top-ranked higher education institutions in the world for academic influence and commercial impact, according to an international assessment.. We ranked ‘excellent’ – the top mark available – in 10 separate categories in this year's 2021 U-Multirank report, an annual independent evaluation funded by the European Commission.